FrancophonIA/ELRC3.0 huggingface dataset:
English: In another study with intravenous administration of midazolam, EMEND was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and 2 mg midazolam was given intravenously prior to the administration of the 3-day regimen of EMEND and on Days 4, 8, and 15.
Croatian: U drugom je ispitivanju intravenske primijene midazolama, EMEND primijenjen u dozi od 125 mg 1. dana te 80 mg na dan 2. i 3. dan liječenja, a midazolam je primijenjen intravenski u dozi od 2 mg, prije primjene trodnevnog režima liječenja lijekom EMEND 4., 8. i 15. dan.
English: See the product information for the selected 5-HT3 antagonist for the appropriate dosing information
Croatian: Vidjeti podatke o lijeku za odabrani antagonist 5-HT3 za odgovarajuće informacije o doziranju
English: See the product information for the selected 5-HT3 antagonist for appropriate dosing information none none none
Croatian: Vidjeti podatke o lijeku za odabrani antagonist 5-HT3 za odgovarajuće informacije o doziranju ništa ništa ništa
English: Vascular disorders hot flush/flushing uncommon
Croatian: Krvožilni poremećaji navale vrućine /crvenilo uz osjećaj vrućine manje često
English: Alternative non-hormonal back-up methods of contraception should be used during treatment with EMEND and for 2 months following the last dose of EMEND (see section 4.5).
Croatian: Dok traje liječenje lijekom EMEND i 2 mjeseca nakon uzimanja posljednje doze lijeka EMEND treba koristiti zamjenske odnosno dodatne nehormonske metode kontracepcije (vidjeti dio 4.5).
English: Renal and urinary disorders dysuria uncommon pollakiuria rare
Croatian: Poremećaji bubrega i mokraćnog sustava dizurija manje često polakizurija rijetko
English: EMEND, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of tolbutamide (a CYP2C9 substrate) by 23 % on Day 4, 28 % on Day 8, and 15 % on Day 15, when a single dose of tolbutamide 500 mg was administered orally prior to the administration of the 3-day regimen of EMEND and on Days 4, 8, and 15.
Croatian: Kad je tolbutamid primijenjen u jednokratnoj peroralnoj dozi od 500 mg prije trodnevnog režima liječenja lijekom EMEND te 4., 8. i 15. dana liječenja, EMEND u dozi od 125 mg na dan 1. dan i u dozi od 80 mg na dan 2. i 3. dan liječenja smanjio je AUC tolbutamida (supstrata CYP2C9) za 23% 4. dan, za 28% 8. dan te za 15% 15. dan.
English: Place the cap on the oral dispenser until it clicks.
Croatian: Zatvorite oralni dozator poklopcem tako da škljocne na mjesto.
English: If you or the child gets any side effects, talk to your doctor, pharmacist, or nurse.
Croatian: Ako primijetite bilo koju nuspojavu kod sebe ili djeteta, potrebno je obavijestiti liječnika, ljekarnika ili medicinsku sestru.
English: The effect of aprepitant on the plasma concentrations of intravenously administered CYP3A4 substrates is expected to be smaller.
Croatian: Očekuje se da će utjecaj aprepitanta na koncentraciju tih djelatnih tvari u plazmi biti manji daju li se intravenski.
English: What EMEND looks like and contents of the pack The 40 mg hard capsule is opaque with a white body and mustard yellow cap with “464” and “40 mg” printed radially in black ink on the body.
Croatian: EMEND 40 mg tvrda kapsula je neprozirna, s bijelim tijelom i žućkastom kapicom te poprečno otisnutim crnim oznakama "464" i "40 mg" na tijelu kapsule.
English: EU/1/03/262/004 1 hard capsule EU/1/03/262/005 5 x 1 hard capsule
Croatian: EU/1/03/262/004 1 tvrda kapsula EU/1/03/262/005 5 x 1 tvrda kapsula
English: The total exposure of orally administered CYP3A4 substrates may increase up to approximately 1.5-fold after a single 40 mg dose of aprepitant; the effect of aprepitant on the plasma concentrations of intravenously administered CYP3A4 substrates is expected to be smaller.
Croatian: CYP3A4 koji se primjenjuju peroralno može narasti do približno 1,5 puta; očekuje se da će utjecaj aprepitanta na koncentraciju tih lijekova u plazmi biti manji daju li se intravenski.
English: It is important that you tell your doctor if you are breast-feeding or are planning to breast-feed before taking this medicine.
Croatian: Važno je da prije uzimanja ovog lijeka obavijestite liječnika ako dojite ili namjeravate dojiti.
English: The oral suspension can be kept at room temperature (not above 30 oC) for up to 3 hours,
Croatian: Oralna suspenzija se prije primjene može čuvati na sobnoj temperaturi (ne iznad 30°C) do 3 sata.
English: Methylprednisolone: The usual intravenously administered methylprednisolone dose should be reduced approximately 25 %, and the usual oral methylprednisolone dose should be reduced approximately 50 % when co-administered with EMEND 125 mg/80 mg regimen.
Croatian: Pri istodobnoj primjeni s režimom liječenja lijekom EMEND 125 mg/80 mg uobičajenu intravensku dozu metilprednizolona treba smanjiti za približno 25%, a uobičajenu peroralnu dozu za približno 50%.
English: Infants, toddlers and children (aged 6 months to less than 12 years, and not less than 6 kg) EMEND is given for 3 days as part of a regimen that includes a 5-HT3 antagonist.
Croatian: Dojenčad, mala djeca i djeca (u dobi od 6 mjeseci do manje od 12 godina i tjelesne težine ne manje od 6 kg)
English: EU/1/03/262/007 1 hard capsule EU/1/03/262/008 5 x 1 hard capsule
Croatian: EU/1/03/262/007 1 tvrda kapsula EU/1/03/262/008 5 x 1 tvrda kapsula
English: - If the child gets any side effects, talk to the doctor, pharmacist, or nurse.
Croatian: - Ako u djeteta primijetite bilo koju nuspojavu, potrebno je obavijestiti liječnika, ljekarnika ili medicinsku sestru.
English: When a single 125 mg dose of EMEND was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilised on chronic warfarin therapy, there was no effect of EMEND on the plasma AUC of R(+) or S(-) warfarin determined on Day 3; however, there was a 34 % decrease in S(-) warfarin (a CYP2C9 substrate)
Croatian: Prilikom primjene jednokratne doze lijeka EMEND 125 mg 1. dan te 80 mg na dan 2. i 3. dan liječenja zdravim ispitanicima čije je stanje stabilizirano kroničnim liječenjem varfarinom, 3. dan liječenja nije opažen nikakav učinak lijeka EMEND na AUC R(+), odnosno S(-) varfarina u plazmi; međutim, 5 dana nakon završetka liječenja lijekom EMEND zamijećeno je sniženje najniže koncentracije S(-) varfarina (supstrata CYP2C9) od 34%, a INR se snizio za 14%.
English: Fertility studies did not indicate direct or indirect harmful effects with respect to mating performance, fertility, embryonic/foetal development, or sperm count and motility (see section 5.3).
Croatian: Ispitivanja plodnosti u životinja nisu ukazala na izravne ili neizravne štetne učinke na učinkovitost parenja, plodnost, embriofetalni razvoj te broj i pokretljivost spermija (vidjeti dio 5.3).
English: Alternative non-hormonal back-up methods of contraception should be used during treatment with EMEND and for 2 months following the last dose of EMEND (see sections 4.4 and
Croatian: Dok traje liječenje lijekom EMEND i 2 mjeseca nakon uzimanja posljednje doze lijeka EMEND treba koristiti zamjenske odnosno dodatne nehormonske metode kontracepcije (vidjeti dijelove 4.4 i 4.5).
English: OUTER CARTON EMEND 125 mg powder for oral suspension
Croatian: VANJSKA KUTIJA EMEND 125 mg prašak za oralnu suspenziju
English: Sachet for EMEND 125 mg powder for oral suspension
Croatian: Vrećica za EMEND 125 mg prašak za oralnu suspenziju
English: General disorders and administration site conditions fatigue common asthenia, malaise uncommon oedema, chest discomfort, gait disturbance rare
Croatian: Opći poremećaji i reakcije na mjestu primjene umor često astenija, slabost manje često edem, osjećaj nelagode u prsima, poremećaj hoda rijetko
English: The medicine can be kept at room temperature (not above 30
Croatian: Prije primjene lijek možete čuvati na sobnoj temperaturi (ne iznad 30°C) do 3 sata.
English: Additional adverse reactions were observed in patients treated with aprepitant for postoperative nausea and vomiting (PONV) and a greater incidence than with ondansetron: abdominal pain upper, bowel sounds abnormal, constipation*, dysarthria, dyspnoea, hypoaesthesia, insomnia, miosis, nausea, sensory disturbance, stomach discomfort, sub-ileus*, visual acuity reduced, wheezing.
Croatian: Postoperative Nausea and Vomiting, PONV) nego u bolesnika koji su primali ondanzetron: bol u gornjem dijelu abdomena, neobični zvukovi u crijevima, konstipacija*, dizartrija, dispneja, hipoestezija, nesanica, mioza, mučnina, poremećaji osjeta, nelagoda u trbuhu, sub-ileus*, smanjena oštrina vida, piskanje pri disanju.
English: The most common adverse reaction reported at a greater incidence in patients treated with the aprepitant regimen than with standard therapy in patients receiving Moderately Emetogenic Chemotherapy (MEC) was fatigue (1.4 % versus 0.9 %).
Croatian: Moderately Emetogenic Chemotherapy MEC) koji su uzimali aprepitant nego u bolesnika na standardnoj terapiji bio je umor (1,4 % naspram 0,9 %).
English: See the product information for the selected 5-HT3 antagonist for appropriate dosing information none none
Croatian: Vidjeti podatke o lijeku za odabrani antagonist 5-HT3 za odgovarajuće informacije o doziranju ništa ništa
English: In healthy young adults, aprepitant accounts for approximately 19 % of the radioactivity in plasma over 72 hours following a single intravenous administration 100-mg dose of [
Croatian: Unutar 72 sata od jednokratne intravenske primjene C]-fosaprepitanta (prolijek aprepitanta) u dozi od 100 mg u zdravih mladih odraslih osoba, oko 19% radioaktivnosti u plazmi otpada na aprepitant, što ukazuje na znatnu prisutnost njegovih metabolita u plazmi.
English: A summary of the key study results is shown in Table 2.
Croatian: Tablici 2 sažeti su ključni rezultati ispitivanja.
English: Lactose (anhydrous) Red iron oxide (E 172) Sodium stearyl fumarate (E 485)
Croatian: 6.1 Popis pomoćnih tvari hidroksipropilceluloza (E 463) natrijev laurilsulfat (E 487) saharoza laktoza (bezvodna) željezov oksid, crveni (E 172) natrijev stearilfumarat (E 485)
English: Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these active substances, potentially causing serious or lifethreatening reactions.
Croatian: Inhibicija CYP3A4 aprepitantom može povisiti koncentracije tih djelatnih tvari u plazmi, što može prouzročiti ozbiljne ili za život opasne reakcije.
English: See the Summary of Product Characteristics (SmPC) for the selected 5-HT3 antagonist for appropriate dosing information.
Croatian: Vidjeti sažetak opisa svojstava lijeka za odabrani antagonist 5-HT3 zbog informacija o odgovarajućem doziranju.
English: 500-1,500 mg/m 2 and doxorubicin (< 60 mg/m 2) or epirubicin (< 100 mg/m 2), aprepitant in combination with an ondansetron/dexamethasone regimen (see section 4.2) was compared with standard therapy (placebo plus ondansetron 8 mg orally (twice on Day 1, and every 12 hours on Days 2 and 3) plus dexamethasone 20 mg orally on Day 1).
Croatian: U randomiziranom, dvostruko slijepom kliničkom ispitivanju s ukupno 866 odraslih bolesnika (864 žene i 2 muškarca) na kemoterapiji ciklofosfamidom u dozi od 750-1500 mg/m2, odnosno kombinacijom ciklofosfamida u dozi od 500-1500 mg/m 2 s doksorubicinom (≤60 mg/m 2) ili epirubicinom (≤100 mg/m2), uspoređeni su režim liječenja aprepitantom u kombinaciji s ondanzetronom/deksametazonom (vidjeti dio 4.2) i standardnom terapijom (placebo s ondanzetronom u peroralnoj dozi od 8 mg dvaput na dan 1. dan te svakih 12 sati 2. i 3. dan i deksametazonom u peroralnoj dozi od 20 mg 1. dan).
English: If the child gets any side effects, talk to the doctor, pharmacist, or nurse.
Croatian: Ako primijetite bilo koju nuspojavu kod djeteta, potrebno je obavijestiti liječnika, ljekarnika ili medicinsku sestru.
English: Stop giving this medicine and see a doctor straight away if you notice any of the serious side effects above.
Croatian: Ako primijetite bilo koju od gore navedenih ozbiljnih nuspojava, prestanite davati ovaj lijek i odmah posjetite liječnika.
English: A summary of the key study results is shown in Table 3.
Croatian: U tablici 3 sažeti su ključni rezultati ispitivanja.
English: See the product information for the selected 5-HT3 antagonist for appropriate dosing information.
Croatian: Vidjeti informacije o lijeku za odabrani antagonist 5-HT3 za odgovarajuće informacije o doziranju.
English: EMEND should be used with caution in patients receiving concomitant active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, ergot alkaloid derivatives, fentanyl, and quinidine (see section 4.5).
Croatian: EMEND se mora primjenjivati uz oprez u bolesnika koji istodobno primaju djelatne tvari koje se metaboliziraju prvenstveno putem CYP3A4 i imaju uski terapijski indeks, kao što su ciklosporin, takrolimus, sirolimus, everolimus, alfentanil, derivati ergot alkaloida, fentanil i kinidin (vidjeti dio 4.5).
English: In healthy young adults, aprepitant accounts for approximately 19 % of the radioactivity in plasma over 72 hours following a single intravenous administration 100 mg dose of [
Croatian: Unutar 72 sata od jednokratne intravenske primjene C]-fosaprepitanta (prolijek aprepitanta) u dozi od 100 mg u zdravih mladih odraslih osoba, oko 19%
English: Alternative non-hormonal back-up methods of contraception should be used during treatment with EMEND and for 2 months following the last dose of EMEND.
Croatian: Dok traje liječenje lijekom EMEND i 2 mjeseca nakon uzimanja posljednje doze lijeka EMEND treba koristiti zamjenske odnosno dodatne nehormonske metode kontracepcije.
English: bloating - urinating more often or passing more urine than normal, sugar or blood in urine - chest discomfort, swelling, change in the manner of walking - cough, mucus in the back of the throat, throat irritation, sneezing, sore throat - eye discharge and itching - ringing in the ears - muscle spasms, muscle weakness - feeling very thirsty - slow heartbeat, heart and blood vessel disease - low number of white blood cells, low sodium levels in the blood, weight loss.
Croatian: Stevens-Johnsonov sindrom ili toksična epidermalna nekroliza (rijetke teške kožne reakcije), - euforija (osjećaj ekstremne sreće), osjećaj smetenosti - bakterijska infekcija, gljivična infekcija - teški zatvor, vrijed na želucu, upala tankog i debelog crijeva, ranice u ustima, nadutost - učestalo mokrenje, mokrenje više nego uobičajeno, prisutnost glukoze ili krvi u mokraći - nelagoda u prsima, oticanje, promjene u načinu hoda - kašalj, slijevanje sluzi u grlo, nadraženost grla, kihanje, upala grla - svrbež i iscjedak iz oka - zujanje u ušima - grčevi u mišićima, slabost mišića - osjećaj jake žeđi - usporeni otkucaji srca, bolest srca i krvnih žila - nizak broj bijelih krvnih stanica, snižene vrijednosti natrija u krvi, gubitak tjelesne težine.
English: EMEND, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of methylprednisolone, a CYP3A4 substrate, by 1.3-fold on Day 1 and by 2.5-fold on Day 3, when methylprednisolone was co-administered intravenously as 125 mg on Day 1 and orally as 40 mg on Days 2 and 3.
Croatian: Istodobna primjena metilprednizolona primijenjenog intravenski u dozi od 125 mg 1. dan liječenja i peroralno u dozi od 40 mg 2. i 3. dan liječenja s lijekom EMEND u dozi od 125 mg 1. dan liječenja te u dozi od 80 mg na dan 2. i 3. dan liječenja povisila je AUC metilprednizolona, supstrata CYP3A4, 1. dan liječenja 1,3 puta, odnosno 2,5 puta 3. dan liječenja.
English: This is not considered to be clinically important.
Croatian: Ovaj nalaz se ne smatra klinički značajnim.
English: EMEND should be used with caution in patients receiving concomitant orally administered active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, ergot alkaloid derivatives, fentanyl, and quinidine (see section 4.5).
Croatian: EMEND se mora primjenjivati uz oprez u bolesnika koji istodobno peroralno primaju djelatne tvari koje se metaboliziraju prvenstveno putem CYP3A4 i imaju uski terapijski indeks, kao što su ciklosporin, takrolimus, sirolimus, everolimus, alfentanil, derivati ergot alkaloida, fentanil i kinidin (vidjeti dio 4.5).
English: Co-administration with warfarin (a CYP2C9 substrate) In patients on chronic warfarin therapy, the International Normalised Ratio (INR) should be monitored closely during treatment with EMEND and for 14 days following each 3-day course of EMEND (see section 4.5).
Croatian: International Normalised Ratio, INR) treba strogo nadzirati za vrijeme liječenja lijekom EMEND i tijekom 14 dana nakon svakog trodnevnog režima primjene lijeka EMEND (vidjeti dio 4.5).
English: Caution is advised during concomitant administration of EMEND and orally administered active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, diergotamine, ergotamine, fentanyl, and quinidine (see section 4.4).
Croatian: Savjetuje se oprez kad se EMEND primjenjuje istodobno s djelatnim tvarima koje se primjenjuju peroralno i metaboliziraju prvenstveno putem CYP3A4 te imaju uski terapijski indeks, kao što su ciklosporin, takrolimus, sirolimus, everolimus, alfentanil, diergotamin, ergotamin, fentanil i kinidin (vidjeti dio 4.4).
English: Caution is advised during concomitant administration of EMEND and active substances that are metabolised primarily through CYP3A4 and with a narrow therapeutic range, such as cyclosporine, tacrolimus, sirolimus, everolimus, alfentanil, diergotamine, ergotamine, fentanyl, and quinidine (see section 4.4).
Croatian: Preporučuje se oprez kad se EMEND primjenjuje zajedno s djelatnim tvarima koje se metaboliziraju prvenstveno putem CYP3A4 i imaju uski terapijski indeks, kao što su ciklosporin, takrolimus, sirolimus, everolimus, alfentanil, diergotamin, ergotamin, fentanil i kinidin (vidjeti dio 4.4).
English: • The oral suspension can be kept at room temperature (not above 30°C) for up to 3 hours, prior to administration.
Croatian: • Prije primjene, oralna suspenzija se može čuvati na sobnoj temperaturi (ne iznad 30°C) do 3 sata.
English: Merck Sharp & Dohme B.V. Tel: 0800 9999000
Croatian: Tel: 0800 9999000
English: It belongs to a group of medicines called ‘neurokinin 1 (NK1) receptor antagonists'.
Croatian: EMEND sadrži djelatnu tvar „aprepitant“, koja pripada skupini lijekova nazvanih "antagonisti neurokinin 1 (NK1) receptora".
English: Respiratory, thoracic and mediastinal disorders dyspnoea, wheezing uncommon
Croatian: Poremećaji dišnog sustava, prsišta i sredoprsja dispneja, piskanje u plućima manje često
English: The potential effects of increased plasma concentrations of midazolam or other benzodiazepines metabolised via CYP3A4 (alprazolam, triazolam) should be considered when co-administering these medicinal products with EMEND (125 mg/80 mg).
Croatian: Pri istodobnoj primjeni s lijekom EMEND (125 mg/80 mg) potrebno je razmotriti mogući učinak na povišenje koncentracije midazolama ili drugih benzodiazepina koji se metaboliziraju putem CYP3A4 (alprazolama, triazolama) u plazmi.
English: The most common adverse reaction reported at a greater incidence in patients treated with the 3-day oral aprepitant regimen than with standard therapy in patients receiving Moderately Emetogenic Chemotherapy (MEC) was fatigue (1.4 % versus 0.9 %).
Croatian: Najčešće nuspojave prijavljene s većom incidencijom u odraslih koji su u trodnevnom režimu liječenja uzimali peroralni aprepitant nego standardnu terapiju među bolesnicima koji su primali jako emetogenu kemoterapiju (engl.
English: • Risk management plan (RMP) Not applicable.
Croatian: • Plan upravljanja rizicima (RMP) Nije primjenjivo.
English: You may take Matever with or without food.
Croatian: Matever možete uzeti sa ili bez hrane.
English: Check with your doctor or pharmacist if you are not sure.
Croatian: Provjerite liječnikom ili ljekarnikom ako niste sigurni.
English: 153 51 Greece
Croatian: 153 51 Grčka
English: The pharmacokinetic and safety profiles did not identify any safety concerns.
Croatian: Farmakokinetički i sigurnosni profili nisu identificirali niti jednu sigurnosnu zabrinutost.
English: Matever is used:
Croatian: Matever se koristi:
English: When you will first start taking Matever, your doctor will prescribe you a lower dose during 2 weeks before giving you the lowest general dose.
Croatian: Kad prvi put počnete uzimati Matever, liječnik će Vam propisati manju dozu tijekom 2 tjedna prije davanja najmanje uobičajene doze.
English: After dilution the infusion is stable for 24 hours at 2 °C - 8 °C (in a refrigerator).
Croatian: Nakon razrjedivanja infuzija je stabilna tijekom 24 sata pri 2°C - 8°C (u hladnjaku).
English: Date of first authorisation: 03 October 2011 Date of latest renewal: 29 June 2016
Croatian: Datum posljednje obnove odobrenja: 29. lipanj 2016.
English: What Matever is and what it is used for
Croatian: Što je Matever i za što se koristi
English: • A small number of people being treated with anti-epileptics such as Matever have had thoughts of harming or killing themselves.
Croatian: • mali broj ljudi liječenih antiepilepticima kao što je Matever imali su misli o samoozljeđivanju ili samoubojstvu.
English: If you take more Matever than you should
Croatian: Ako uzmete više Matevera nego što ste trebali
English: The lowest effective dose should be used.
Croatian: Treba koristiti najnižu učinkovitu dozu.
English: Matever is indicated as adjunctive therapy
Croatian: Matever je indiciran kao dodatna terapija
English: Cases of encephalopathy generally occurred at the beginning of the treatment (few days to a few months) and were reversible after treatment discontinuation.
Croatian: Slučajevi encefalopatije općenito su se pojavljivali na početku liječenja (od nekoliko dana do nekoliko mjeseci) te su bili reverzibilni kada je liječenje prekinuto.
English: If you have any symptoms of depression and/or suicidal ideation, please contact your doctor.
Croatian: Ako imate bilo kakve simptome depresije i/ili samoubilačke ideje, molimo obavijestite svog liječnika.
English: A doctor or a nurse will administer you Matever as an intravenous infusion.
Croatian: Liječnik ili medicinska sestra će Vam primijeniti Matever u obliku intravenske infuzije.
English: What Matever looks like and contents of the pack
Croatian: Kako Matever izgleda i sadržaj pakiranja
English: Matever must be taken twice a day, once in the morning and once in the evening, at about the same time each day.
Croatian: Matever se mora uzimati dva puta na dan, jednom ujutro i jednom navečer, u približno isto vrijeme svaki dan.
English: The use of Matever in accordance with the product information is not likely to result in an unacceptable environmental impact (see section 6.6).
Croatian: Primjena Matevera u skladu s informacijama o lijeku vjerojatno neće dovesti do neprihvatljivog učinka na okoliš (vidjeti dio 6.6).
English: The following information is intended for healthcare professionals only: Directions for the proper use of Matever is provided in section 3.
Croatian: Sljedeće informacije namijenjene su samo zdravstvenim djelatnicima: Uputa za pravilnu primjenu Matevera nalazi se u dijelu 3.
English: This is equivalent to 2.86 % of the recommended maximum daily dietary intake of sodium for an adult.
Croatian: To odgovara 2.86 % preporučenog maksimalnog dnevnog unosa soli za odraslu osobu.
English: You should continue Matever treatment for as long as your doctor has told you.
Croatian: Trebate nastaviti liječenje Mateverom onoliko dugo koliko je liječnik odredio.
English: Due to possible different individual sensitivity, some patients might experience somnolence or other central nervous system related symptoms, especially at the beginning of treatment or following a dose increase.
Croatian: . Uslijed mogućih razlika u osjetljivosti među pojedincima u nekih bolesnika može se javiti somnolencija ili drugi simptomi vezani za središnji živčani sustav, osobito na početku liječenja ili nakon povećanja doze.
English: No special precautions for storage prior to reconstitution.
Croatian: Nema posebnih mjera za čuvanje prije rekonstitucije.